secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2026-10-05T12:00:38+00:00
Accession:  0001213900-26-106651
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.07
LLM model:  deepseek-v4.1-flash:cloud@v2

Jasper Therapeutics holders approve 1-for-15 to 1-for-35 reverse split and share increase to 675M
--------------------------------------------------------------------------------

- Proposal 1 approved 21,088,353 to 567,692 (91,820 abstentions): reverse stock split at a ratio of 1-for-15 to 1-for-35, at Board discretion any time on or before December 31, 2026.
- Proposal 2 approved 20,722,644 to 903,655 (121,566 abstentions): authorized common stock rises from 490,000,000 to 675,000,000 shares, effected at Board discretion.
- Proposal 3 (adjournment if needed) approved 20,938,915 to 528,123 (280,827 abstentions); all three proposals passed at the September 30, 2026 special meeting.
- 21,747,865 shares, roughly 65.36% of the 33,274,561 shares outstanding on the August 10, 2026 record date, were represented virtually or by proxy.
- Proposals were detailed in the definitive proxy statement filed with the SEC on September 4, 2026; split would not reduce the authorized share count.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026106651/0001213900-26-106651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026106651/ea0307484-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-106651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer